Skip to main content
About us
Our science
Our Pipeline
Partnering
News & Events
Contact
About us
Our science
Our Pipeline
Partnering
News & Events
Contact
In the news
Press releases
Archive
Dec 23, 2024
Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Dec 5, 2024
Galimedix Therapeutics initiates Phase 1 study with oral small molecule, GAL-101, an amyloid beta (Aβ) aggregation modulator
Jun 10, 2024
Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101
Upcoming Events
BIO-Europe Spring 2025
MARCH 17-19, 2025
Innovation in Ophthalmology 2025
MARCH 28-29, 2025
AD/PD 2025 Advances in Science & Therapy
APRIL 1-5, 2025
